RxDoctor Payments DataLook up a doctor →

David Patick, MD

Internal Medicine · Huntington, WVNPI 1972546273

Payments from drug & device makers

$18,032in general payments, 2019–2025

Across 1,386 payments — averaging $13.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • GSK$2K
  • AbbVie$1K
  • Novartis$1K
  • Amgen$1K
  • plus $9K from 51 others

What the payments were for

  • Food & beverage$18,025100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)78$2,098
Novo Nordisk203$1,808
GSK116$1,607
AbbVie(2 entities)99$1,374
Novartis100$1,336
Amgen78$1,075
Lilly USA, LLC62$1,026
Boehringer Ingelheim69$756
Pfizer85$689
Johnson & Johnson(2 entities)80$600
E.r. Squibb & Sons, L.L.C.57$590
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC44$511
Amarin Pharma, Inc.33$431
Paratek Pharmaceuticals, Inc.24$408
Teva Pharmaceuticals USA, Inc.19$280
Bayer13$274
Vifor Pharma, Inc.23$267
Esperion Therapeutics, Inc.18$244
Otsuka America Pharmaceutical, Inc.19$243
Shield Therapeutics Inc10$221
Abbott11$204
Avanir Pharmaceuticals, Inc.25$190
Takeda Pharmaceuticals U.S.A., Inc.12$169
Argenx US, Inc.8$160
Kowa Pharmaceuticals America, Inc.21$145
Sanofi-aventis U.S. LLC10$144
Biohaven Pharmaceutical Holding Company Ltd.7$126
Biohaven Pharmaceuticals, Inc.8$124
Dexcom, Inc.7$112
Mylan Specialty L.p.3$70
Sunovion Pharmaceuticals Inc.4$67
Lundbeck LLC3$60
Intercept Pharmaceuticals, Inc.3$46
Xeris Pharmaceuticals, Inc.2$44
Cvrx, Inc.2$37
Merck2$34
Endo Pharmaceuticals Inc.2$34
Corium, LLC1$30
Shire North American Group Inc2$29
Ironwood Pharmaceuticals, Inc2$29
Aurinia Pharma U.S., Inc.1$28
Genentech USA, Inc.2$27
Corcept Therapeutics2$26
Phathom Pharmaceuticals, Inc.3$24
Philips North America LLC1$23
Kyowa Kirin, Inc.1$21
Insulet Corporation1$21
Baxter Healthcare1$21
Smith+Nephew1$20
Scpharmaceuticals Inc.1$19
Ferring Pharmaceuticals Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Exact Sciences1$18
Melinta Therapeutics, LLC1$16
Boston Scientific1$14
Eisai Inc.1$14
Neurocrine Biosciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,032 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$153,763
Medicare patients
488
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$321,873
Tresiba Flextouch U-200Insulin Degludec120$240,503
JardianceEmpagliflozin156$169,045
JanuviaSitagliptin Phosphate142$168,921
OzempicSemaglutide146$158,606
MounjaroTirzepatide90$97,663
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$94,967
XareltoRivaroxaban69$83,982
OtezlaApremilast12$54,498
TrulicityDulaglutide44$47,457
Breo ElliptaFluticasone/Vilanterol61$36,832
EntrestoSacubitril/Valsartan33$36,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$29,794
LinzessLinaclotide26$29,608
Levemir FlexpenInsulin Detemir41$18,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$689$321,873322 claims
Boehringer IngelheimJardiance$756$169,045156 claims
MerckJanuvia$34$168,921142 claims
Novo NordiskOzempic$1,808$158,606146 claims
Lilly USA, LLCMounjaro, Trulicity$1,026$145,120134 claims
Johnson & JohnsonXarelto$600$83,98269 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$1,607$77,524126 claims
AmgenOtezla$1,075$54,49812 claims
AbbVieLinzess, Synthroid, Restasis$1,374$43,902145 claims
NovartisEntresto$1,336$36,45733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →